Inspire Announces Presentations at Two European Scientific
Conferences

DURHAM, N.C.--(BUSINESS WIRE)--Jun 12, 2007 - Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
scientists and collaborators related to Inspire will present
information at the XXVI Congress of the European Academy of
Allergology and Clinical Immunology (EAACI) being held June 9-13,
2007 in Goteborg, Sweden and at the 30th European Cystic Fibrosis
Society (ECFS) Conference being held June 13-16, 2007 in Belek,
Turkey.

The EAACI Congress includes two presentations with clinical data
on bilastine, a compound in development by FAES Farma, S.A. for the
treatment of allergic rhinitis, which is partnered with Inspire in
the United States and Canada, and one presentation with scientific
data on epinastine, bilastine and other antihistamines for treating
allergies. -0-

-- A Phase 3 Study Comparing the Efficacy and Safety of Once Daily
Bilastine with Cetirizine and Placebo for the Treatment of Seasonal
Allergic Rhinitis
Poster and brief oral presentation on Tuesday, June 12, 2007
-- Treatment with Bilastine Improves Symptoms in Patients with
Seasonal Allergic Rhinitis (Phase 3 Study Comparing the Efficacy
and Safety of Once Daily Bilastine with Desloratadine and Placebo
for the Treatment of Seasonal Allergic Rhinitis)
Poster and brief oral presentation on Tuesday, June 12, 2007
-- Evaluation of Muscarinic Receptor Antagonism by Antihistamines
Poster and brief oral presentation on Tuesday, June 12, 2007

The ECFS Conference includes two presentations with clinical
data on denufosol, a compound in development by Inspire for the
treatment of cystic fibrosis. -0-

-- Deposition and Pharmacokinetic Studies with Inhaled P2Y2 Agonists -
Evidence of High Lung Delivery and Minimal Systemic Exposure
Poster presentation on Thursday and Friday, June 14-15, 2007 and
oral presentation on Thursday, June 14, 2007
-- Reactive Airway Disease and Cystic Fibrosis: a Retrospective
Analysis of the Safety and Tolerability with Denufosol Inhalation
Solution
Poster presentation on Thursday, June 14, 2007 and guided poster
tour on Friday, June 15, 2007

The posters from these presentations will be available following
each related conference on Inspire's website, www.inspirepharm.com,
in the Research & Development section, under Science &
Technology.

About Inspire

Inspire is a biopharmaceutical company dedicated to discovering,
developing and commercializing prescription pharmaceutical products
in disease areas with significant commercial potential and unmet
medical needs. Inspire employs a U.S. sales force for the promotion
of AzaSite(TM) (azithromycin ophthalmic solution) 1% for bacterial
conjunctivitis, Elestat(R) (epinastine HCI ophthalmic solution)
0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine
ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the
therapeutic areas of ophthalmology and respiratory/allergy, and is
developing products for dry eye, cystic fibrosis, allergic rhinitis
and glaucoma. Elestat and Restasis are trademarks owned by
Allergan, Inc. AzaSite is a trademark owned by InSite Vision
Incorporated. For more information, visit www.inspirepharm.com.

Forward-Looking Statements

The forward-looking statements in this news release relating to
management's expectations and beliefs are based on preliminary
information and management assumptions. Such forward-looking
statements are subject to a wide range of risks and uncertainties
that could cause results to differ in material respects, including
those relating to product development, revenue, expense and
earnings expectations, the seasonality of Elestat, intellectual
property rights, adverse litigation developments, adverse
developments in the U.S. Securities and Exchange Commission (SEC)
investigation, competitive products, results and timing of clinical
trials, success of marketing efforts, the need for additional
research and testing, delays in manufacturing, funding, and the
timing and content of decisions made by regulatory authorities,
including the U.S. Food and Drug Administration. Further
information regarding factors that could affect Inspire's results
is included in Inspire's filings with the SEC. Inspire undertakes
no obligation to publicly release the results of any revisions to
these forward-looking statements that may be made to reflect events
or circumstances after the date hereof.